Merck’s Vioxx Conduct Receives Passing Grade In Review By Outside Firm
An independent report contracted by Merck has concluded that the company's senior executives did not mishandle the development, testing and marketing of Vioxx (rofecoxib), despite the fact that the product is widely viewed as one of the more significant debacles in pharmaceutical history
You may also be interested in...
The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication
Following Merck's decision to withdraw Vioxx from the market, an FDA approval of the follow-on COX-2 inhibitor Arcoxia is likely to be delayed
The Vioxx labeling change will allow Merck to discuss the COX-2 inhibitor's cardiovascular safety profile in the context of a rheumatoid arthritis indication and a gastrointestinal safety benefit